{"nctId":"NCT01890759","briefTitle":"Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation","startDateStruct":{"date":"2013-06-25","type":"ACTUAL"},"conditions":["Meningitis","Meningococcal Infection"],"count":300,"armGroups":[{"label":"Meningococcal Diphtheria Toxoid Vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: Meningococcal Diphtheria Toxoid Vaccine"]}],"interventions":[{"name":"Meningococcal Diphtheria Toxoid Vaccine","otherNames":["Menactra®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female subjects aged 9 to 17 months on the day of inclusion\n* Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative(s) (if applicable)\n* Subject and parent/legally acceptable representative (if applicable) able to attend all scheduled visits and to comply with all trial procedures.\n\nExclusion Criteria:\n\n* Participation in the 4 weeks preceding inclusion or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.\n* Receipt of any vaccine in the 4 weeks preceding each trial vaccination or planned receipt of any vaccine in the 4 weeks following each trial vaccination, except for:\n* (i) influenza vaccination, which may be received at least 2 weeks before study vaccines.\n* (ii) measles (M) or measles, mumps, rubella (MMR) routine vaccination, which can be administered concomitantly with the first dose of study vaccine as per routine immunization schedule\n* (iii) for subjects enrolled at Indian sites: oral poliomyelitis vaccine (OPV) received during National Immunization Days (NIDs) and supplementary immunization activity days (SIADs)\n* Previous vaccination against meningococcal disease with either the study vaccine or another meningococcal vaccine\n* Receipt of immune globulins, blood or blood-derived products in the past 3 months\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n* History of meningococcal diseases, confirmed either clinically, serologically, or microbiologically\n* At high risk, in the opinion of the Investigator, for meningococcal disease during the trial\n* Known or suspected systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances\n* Known thrombocytopenia, contraindicating intramuscular vaccination\n* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination\n* In an emergency setting, or hospitalized involuntarily\n* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion\n* For subjects enrolled at Indian sites: Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C).\n* For subjects enrolled at Russian sites: Acute disease of any severity on the day of vaccination or febrile illness (axillary temperature ≥ 37.0°C).\n\nA prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.\n\n* Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw\n* Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study\n* Personal history of Guillain-Barré Syndrome.","healthyVolunteers":true,"sex":"ALL","minimumAge":"9 Months","maximumAge":"17 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Seroprotection Using a Serum Bactericidal Assay Human Complement With Antibody Titers ≥ 1:8 for Meningococcal Serogroups A, C, Y, and W-135 Before and Following Vaccination With Menactra®","description":"Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-HC assay. Seroprotection was defined as antibody titers ≥ 1:8.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null},{"groupId":"OG001","value":"55.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null},{"groupId":"OG001","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"6.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.1","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving the Threshold Using a Serum Bactericidal Assay Human Complement With Antibody Titers ≥ 1:4 for Meningococcal Serogroups A, C, Y, and W-135 Before and Following Vaccination With Menactra®","description":"Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-HC assay. The threshold was defined as antibody titers ≥ 1:4.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","spread":null},{"groupId":"OG001","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":null},{"groupId":"OG001","value":"14.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"11.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With At Least Four-Fold Rise in Threshold in Meningococcal Serogroups A, C, Y, and W-135 Antibody Titers by Serum Bactericidal Assay Using Human Complement Following Vaccination With Menactra®","description":"Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-HC assay.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"84.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null},{"groupId":"OG001","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"97.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving the Threshold in Meningococcal Serogroups A, C, Y, and W-135 Antibody Titers ≥ 1:8 by Serum Bactericidal Assay Using Human Complement Before and Following Vaccination With Menactra®","description":"Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-HC assay. The threshold was defined as antibody titers ≥ 1:8.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null},{"groupId":"OG001","value":"55.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null},{"groupId":"OG001","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"6.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.1","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving the Threshold in Meningococcal Serogroups A, C, Y, and W-135 Antibody Titers ≥ 1:8 by Serum Bactericidal Assay Using Baby Rabbit Complement Before and Following Vaccination With Menactra®","description":"Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-BR assay. The threshold was defined as antibody titers ≥ 1:8.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.3","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"10.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null},{"groupId":"OG001","value":"94.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.2","spread":null},{"groupId":"OG001","value":"84.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6","spread":null},{"groupId":"OG001","value":"18.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving the Threshold in Meningococcal Serogroups A, C, Y, and W-135 Antibody Titers ≥ 1:4 by Serum Bactericidal Assay Using Human Complement Before and Following Vaccination With Menactra®","description":"Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-HC assay. The threshold was defined as antibody titers ≥ 1:4.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","spread":null},{"groupId":"OG001","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":null},{"groupId":"OG001","value":"14.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"11.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving the Threshold in Meningococcal Serogroups A, C, Y, and W-135 Antibody Titers ≥ 1:4 by Serum Bactericidal Assay Using Baby Rabbit Complement Before and Following Vaccination With Menactra®","description":"Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-BR assay. The threshold was defined as antibody titers ≥ 1:4.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":null},{"groupId":"OG001","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"11.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null},{"groupId":"OG001","value":"94.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.2","spread":null},{"groupId":"OG001","value":"84.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6","spread":null},{"groupId":"OG001","value":"19.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With At Least Four-Fold Rise in Threshold Meningococcal Serogroups A, C, Y, and W-135 Antibody Titers by Serum Bactericidal Assay Using Human Complement Following Vaccination With Menactra®","description":"Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-HC assay.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"84.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null},{"groupId":"OG001","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"97.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With At Least Four-Fold Rise in Meningococcal Serogroups A, C, Y, and W-135 Antibody Titers by Serum Bactericidal Assay Using Baby Rabbit Complement Following Vaccination With Menactra®","description":"Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-BR assay.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"96.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","spread":null},{"groupId":"OG001","value":"92.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":null},{"groupId":"OG001","value":"66.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.1","spread":null},{"groupId":"OG001","value":"96.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Bactericidal Assay Using Human Complement Antibody Geometric Mean Titers of Meningococcal Serogroups A, C, Y, and W-135 Before and Following Vaccination With Menactra®","description":"Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-HC assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.73","spread":null},{"groupId":"OG001","value":"6.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"171","spread":null},{"groupId":"OG001","value":"95.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.46","spread":null},{"groupId":"OG001","value":"2.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":null},{"groupId":"OG001","value":"128","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.35","spread":null},{"groupId":"OG001","value":"2.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.9","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","spread":null},{"groupId":"OG001","value":"2.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"201","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Bactericidal Assay Using Baby Rabbit Complement Geometric Mean Titers of Meningococcal Serogroups A, C, Y, and W-135 Before and Following Vaccination With Menactra®","description":"Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-BR.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.47","spread":null},{"groupId":"OG001","value":"2.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1940","spread":null},{"groupId":"OG001","value":"1426","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":null},{"groupId":"OG001","value":"3.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"326","spread":null},{"groupId":"OG001","value":"781","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null},{"groupId":"OG001","value":"95.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"734","spread":null},{"groupId":"OG001","value":"805","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.66","spread":null},{"groupId":"OG001","value":"4.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1260","spread":null},{"groupId":"OG001","value":"1134","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Bactericidal Assay Using Human Complement Antibody Geometric Mean Titer Ratios of Meningococcal Serogroups A, C, Y, and W-135 Following Vaccination With Menactra®","description":"Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-HC assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"13.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"51.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.4","spread":null},{"groupId":"OG001","value":"41.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":null},{"groupId":"OG001","value":"82.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Bactericidal Assay Using Baby Rabbit Complement Geometric Mean Titer Ratios of Meningococcal Serogroups A, C, Y, and W-135 Before and Following Vaccination With Menactra®","description":"Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-BR assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"305","spread":null},{"groupId":"OG001","value":"540","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"240","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.45","spread":null},{"groupId":"OG001","value":"8.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"223","spread":null},{"groupId":"OG001","value":"246","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Solicited Injection Site or Systemic Reactions Following Each Vaccination With Menactra®","description":"Injection site: Tenderness, Erythema, and Swelling. Systemic: Fever (Temperature), Vomiting, Crying abnormal, Drowsiness, Appetite lost, Irritability. Grade 3 Injection site: Tenderness, Cries when injected limb is moved or the movement of the injected limb is reduced. Erythema and Swelling, ≥50 mm. Grade 3 Systemic: Fever, \\>39.5C; Vomiting, ≥6 episodes per 24 hours or requiring parenteral hydration; Crying abnormal, \\>3 hours; Drowsiness, Sleeping most of the time or difficult to wake; Appetite lost, Refuses ≥3 feeds/meals or refuses most feeds/meals; Irritability, Inconsolable.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"14.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"3.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":null},{"groupId":"OG001","value":"10.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"9.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"12.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"9.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"17.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null},{"groupId":"OG001","value":"14.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":null},{"groupId":"OG001","value":"9.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":100},"commonTop":["Injection site Tenderness","Irritability","Appetite lost","Crying abnormal","Injection site Erythema"]}}}